Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Marcellin P., Lau G., Bonino F., Farci P., Hadziyannis S., Jin R., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.351, no.12, pp.1206-1217, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 351 Issue: 12
  • Publication Date: 2004
  • Doi Number: 10.1056/nejmoa040431
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1206-1217
  • Bursa Uludag University Affiliated: Yes

Abstract

Background: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.